Diatrizoate

證據等級: L5

預測適應症: 10 個

Diatrizoate: From Radiographic Contrast Agent to Osteoarthritis Susceptibility

One-Sentence Summary

Diatrizoate is an ionic iodinated contrast agent used primarily for radiographic imaging procedures such as urography, angiography, and arthrography. The TxGNN model predicts it may be effective for Osteoarthritis Susceptibility (rank #1, score 99.08%), yet no clinical trials or publications directly support a therapeutic role — and evidence for the related hemoglobinopathy prediction (rank #4) documents active harm rather than benefit. All 10 predicted indications are at the lowest evidence tier (L5), and the predictions appear to reflect diagnostic co-occurrence in the knowledge graph rather than genuine therapeutic relationships.

Quick Overview

Item	Content
Original Indication	Radiographic contrast agent for imaging procedures
Predicted New Indication	Osteoarthritis Susceptibility
TxGNN Prediction Score	99.08%
Evidence Level	L5
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for diatrizoate in this evidence pack. Based on known pharmacological properties, diatrizoate is an ionic, high-osmolality iodinated contrast medium belonging to the triiodobenzoic acid derivative class. Its high iodine content renders it radiopaque, enabling visualization of body cavities, vasculature, and joint spaces during imaging — its established clinical role.

The TxGNN model’s clustering of diatrizoate with musculoskeletal conditions (osteoarthritis susceptibility, osteoarthritis, rheumatoid arthritis — ranks 1, 2, 3) most likely originates from the EPIC (Equilibrium Partitioning of Ionic Contrast agent) principle: diatrizoate’s negative charge allows it to partition inversely with sulfated glycosaminoglycan (sGAG) content in cartilage matrix, making it useful for EPIC-µCT imaging of cartilage health. This physical-chemistry property has been explored diagnostically (PMID 25602512), but it is a diagnostic principle, not a therapeutic mechanism. No established biological pathway has been proposed by which diatrizoate would treat or prevent osteoarthritis.

A critical concern emerges from the rank-4 prediction (hemoglobinopathy): multiple case reports and observational studies document that diatrizoate, as a hyperosmolar ionic agent, actively induces erythrocyte sickling and acute intravascular hemolysis in patients with sickle cell disorders. The knowledge graph co-occurrence driving these TxGNN predictions reflects adverse event documentation and imaging procedure co-citations, not treatment relationships — illustrating a systematic model limitation for diagnostic agents whose disease co-occurrence is procedural rather than therapeutic.

Clinical Trial Evidence

Currently no related clinical trials registered for osteoarthritis susceptibility.

Context note: Two trials were retrieved under the broader “osteoarthritis” query but are not relevant to diatrizoate as a therapeutic agent:

NCT01279395 — Terminated (n=3); studied anti-inflammatory drugs and cholesterol metabolism; diatrizoate not involved therapeutically.

NCT00550524 — Status unknown (n=5); autologous bone marrow stem cell therapy for knee OA; diatrizoate role, if any, was as an imaging adjunct only.

Literature Evidence

Currently no related literature available for osteoarthritis susceptibility.

Context note: Literature retrieved for related queries (rheumatoid arthritis: 12 publications; osteoarthritis: 4 publications) is exclusively diagnostic in nature — arthrography studies, joint clearance pharmacokinetics, and EPIC-µCT cartilage imaging. Representative publications are listed below for completeness:

PMID	Year	Type	Journal	Key Findings
5788057	1969	Diagnostic Imaging	Br J Radiol	Arthrography of the knee in rheumatoid arthritis — diatrizoate used as imaging contrast, not as treatment
5421242	1970	Pharmacokinetic/Observational	Acta Rheumatol Scand	Clearance of ¹²⁵I-labelled urographin (diatrizoate salt) from RA knee joints — pharmacokinetic observation only
6828677	1983	Diagnostic Imaging	Radiology	Arthrography of traumatized wrist; characterises soft-tissue injuries via contrast — diagnostic use only
25602512	2015	Ex vivo / EPIC-µCT	Connective Tissue Res	EPIC-µCT used to observe sGAG content changes in elderly hip cartilage — diatrizoate as diagnostic tracer
1147166	1975	Diagnostic Imaging	Am J Roentgenol	Arthrography in hip osteoarthritis — diagnostic application

All retrieved literature documents diagnostic or procedural uses only. None supports a therapeutic role in any musculoskeletal indication.

Canada Market Information

Diatrizoate is not currently marketed in Canada. No Drug Identification Numbers (DINs) are on record with Health Canada.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Critical Safety Signal Identified During Evidence Review

Although structured safety data (formal warnings/contraindications) was not available in this evidence pack, a review of retrieved literature for the rank-4 predicted indication (hemoglobinopathy) reveals the following well-documented adverse effects:

Erythrocyte sickling induction: Diatrizoate, as a hyperosmolar ionic contrast agent, has been documented to induce sickling of red blood cells in vitro and in vivo in patients with sickle cell disease (HbSS, HbSC). See PMID 3985742, 5121421.

Acute intravascular hemolysis: Case reports describe severe hemolysis and pulmonary complications following diatrizoate administration for coronary angiography in patients with HbSC disease. See PMID 3985742, 7313758.

Serious neurological events: Post-angiographic cortical blindness and cerebral infarction reported in a patient with homozygous sickle cell disease. PMID 1601612 explicitly recommends low-osmolar contrast media instead of ionic agents in this population.

Fatal outcome on record: A fatality following selective coronary angiography in a patient with sickle cell haemoglobin is documented. See PMID 4638407.

Any further evaluation of diatrizoate for any therapeutic indication must account for these established harms in patients with haemoglobin disorders and any condition associated with compromised renal function.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications for diatrizoate are evidence level L5 (model prediction only, no therapeutic studies), and the dominant pattern across retrieved evidence is diagnostic/procedural co-occurrence — not biological treatment relationships. The hemoglobinopathy prediction (rank 4, score 98.46%) is uniquely concerning because the existing literature documents serious harm from diatrizoate in that population, not benefit.

To proceed, the following is needed:

Formal MOA characterization: DrugBank/literature review to document complete pharmacological profile of diatrizoate beyond its contrast imaging role
Preclinical therapeutic hypothesis testing: If the EPIC cartilage-penetration property is proposed to have therapeutic value (e.g., modulation of cartilage proteoglycan metabolism), dedicated in vitro and in vivo studies would be required before any clinical consideration
TxGNN model audit for diagnostic agents: A systematic review of how frequently high TxGNN scores for contrast agents and diagnostic tools reflect imaging co-occurrence rather than therapeutic potential — this case may serve as a benchmark for flag rules
Health Canada regulatory review: Confirm current status of all diatrizoate-containing products in Canada (including any historical DIN records) and retrieve the approved product monograph for formal safety review
Safety contraindication mapping: Formal compilation of contraindications (sickle cell disease, severe renal impairment, hypersensitivity to iodinated agents) before any indication expansion is considered

This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require rigorous clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.